Indirect costs of breast cancer in Lithuania in 2008

Ivanaūskienė, Rugile; Padaiga, Žilvinas; Vanagas, Giedrius; Juozaitytė, Elona

doi:10.1016/s1230-8013(10)70003-5

Cited by 3 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty-one studies were included in the review [5][6][7]11,12,22,. [5][6][7]11,12,22,[30][31][32][33][34][35][36][37][38][39][40], 11 in the USA [29,[41][42][43][44][45][46][47][48][49][50], two in Korea [51,53] and one in Puerto Rico [52]. Only one of the studies included multiple countries -a study of costs across countries of the EU [40].…”

Section: Resultsmentioning

confidence: 99%

“…Only one of the studies included multiple countries -a study of costs across countries of the EU [40]. Almost a quarter of the studies produced an 'all cancers' premature mortality cost; breast cancer was the most commonly studied individual cancer site (n = 7) [5,6,12,22,35,47,50] followed by skin (n = 3) [31,33,34], colorectal (n = 2) [49,53] and cervical (n = 2) cancer [22,43]. In relation to premature mortality costs, an incidence-based cost approach considers the productivity lost throughout the lifetime of those who died from cancer in a specific year, while a prevalence-based costs approach considers the lost productivity in a certain year for those who would have been alive in that year if they had not died, either in that year or previous years, from cancer [29].…”

Section: Resultsmentioning

confidence: 99%

“…Several of the US studies included fringe benefits (such as employer contributions to social insurance) on top of standard wages. A few studies used other values including gross domestic product per capita [35], average labor productivity [5,36] and gross value added per employee [38]. The single study using the WTP approach used the value of a year of life [46].…”

Section: Valuation Methodsmentioning

confidence: 99%

“…Twelve studies [5,[30][31][32][33]35,37,[40][41][42]47,51] reported applying a prevalence-based approach costing approach and eight studies [6,7,29,44,45,48,50,52] reported an incidence-based approach. The remainder failed to specify the approach.…”

Section: Costing Approachmentioning

confidence: 99%

“…While all but two [35,36] of the studies reported using discounting, many did not state any adjustment for wage growth over time. Most US studies adjusted estimates for wage growth (assuming a 1% growth figure), whereas only 3 of the 17 European papers accounted for it (1.0-2.6% assumed growth) [11,12,22].…”

Section: Accounting For Time and Labor Market Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

The cost of premature cancer-related mortality: a review and assessment of the evidence

Hanly

Pearce

Sharp

2014

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Worldwide, 8.2 million people die of cancer annually. Cancer has a significant societal impact, impinging on countries' economic health. We reviewed methodological aspects, and the main cost results, of studies calculating premature mortality losses from cancer published 2000-2013 and identified gaps in the evidence-base. Thirty-one studies were identified (Europe, 17; USA, 11; Korea, 2; Puerto Rico, (1). The human capital approach dominated (30 studies); studies differed in how they implemented the methodological approach. Aspects of methodology were poorly reported. Premature cancer-related mortality costs are substantial and appear to be rising. The evidence-base has gaps in relation to cancer sites studied and less developed and emerging economies. Comprehensive, standardised, estimates of premature mortality losses are needed if these measures are to be useful in assessing the societal cancer burden.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Valuation Methodsmentioning

confidence: 99%

Section: Costing Approachmentioning

confidence: 99%

Section: Accounting For Time and Labor Market Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

The cost of premature cancer-related mortality: a review and assessment of the evidence

Hanly

Pearce

Sharp

2014

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014

Łyszczarz

Nojszewska

2017

BMC Cancer

View full text Add to dashboard Cite

BackgroundApart from the health and social burden of the disease, breast cancer (BC) has important economic implications for the sick, health system and whole economy. There has been a growing interest in the economic aspects of breast cancer and analyses of the disease costs seem to be the most explored topic. However, the results from these studies are hardly comparable. With this study we aim to contribute to the field by providing estimates of productivity losses and public finance burden attributable to BC in Poland.MethodsWe used retrospective prevalence-based top-down approach to estimate the productivity losses (indirect costs) of BC in Poland in the period 2010–2014. Human capital method (HCM) and societal perspective were used to estimate the costs of: absenteeism of the sick and caregivers, presenteeism of the sick and caregivers, disability, and premature mortality. We also used figures illustrating public finance burden attributable to the disease. Deterministic sensitivity analysis was performed to assess the stability of the estimates. A variety of data sources were used with the social insurance system and Polish National Cancer Registry being the most important ones.ResultsProductivity losses associated with BC in Poland were €583.7 million in 2010 and they increased to €699.7 million in 2014. Throughout the period these costs accounted for 0.162–0.171% of GDP, an equivalent of 62,531–65,816 per capita GDP. Losses attributable to disability and premature mortality proved to be the major cost drivers with 27.6%–30.6% and 22.0%–24.6% of the total costs respectively. The costs due to caregivers’ presenteeism were negligible (0.1% of total costs). Public finance expenditure for social insurance benefits to BC sufferers ranged from €50.2 million (2010) to €56.6 million (2014), an equivalent of 0.72–0.79% of expenditures for all diseases. Potential losses in public finance revenues accounted for €173.9 million in 2010 and €211.0 million in 2014. Sensitivity analysis showed that the results were robust to changes in the model parameters.ConclusionsThe productivity losses attributable to BC in Poland were a sizable burden for the society. They contributed both to decreased economy output and to public finance deficit.

show abstract

A systemmatic literature review on indirect costs of women with breast cancer

Mohammadpour

Soleimanpour

Javan‐Noughabi

et al. 2022

Cost Eff Resour Alloc

View full text Add to dashboard Cite

Introduction The rising incidence of breast cancer places a financial burden on national health services and economies. The objective of this review is to present a detailed analysis of the research and literature on indirect costs of breast cancer. Methods English literature databases from 2000 to 2020 were searched to find studies related to the objective of the present review. Study selection and data extraction was undertaken independently by two authors. Also, quality assessment was done using a checklist designed by Stunhldreher et al. Results The current study chose 33 studies that were eligible from a total of 2825 records obtained. The cost of lost productivity due to premature death based on human capital approach ranged from $22,386 to $52 billion. The cost burden from productivity lost due to premature death based on friction cost approach ranged from $1488.61 to $4,518,628.5. The cost burden from productivity lost due to morbidity with the human capital approach was reported as $126,857,360.69 to $596,659,071.28. The cost of lost productivity arising from informal caregivers with the human capital approach was $297,548.46 to $308 billion. Conclusion Evaluation of the existing evidence revealed the indirect costs of breast cancer in women to be significantly high. This study did a thorough review on the indirect costs associated with breast cancer in women which could serve as a guide to help pick the appropriate method for calculating the indirect costs of breast cancer based on existing methods, approach and data. There is a need for calculations to be standardised since the heterogeneity of results in different domains from various studies makes it impossible for comparisons to be made among different countries.

show abstract

Indirect costs of breast cancer in Lithuania in 2008

Cited by 3 publications

References 14 publications

The cost of premature cancer-related mortality: a review and assessment of the evidence

The cost of premature cancer-related mortality: a review and assessment of the evidence

Productivity losses and public finance burden attributable to breast cancer in Poland, 2010–2014

A systemmatic literature review on indirect costs of women with breast cancer

Contact Info

Product

Resources

About